Change 5-day change 1-year change 3-year change Capi.($)
-16.67%-16.67% - - 4.97T
+1.44%+10.42%+25.66%+0.67% 19TCr
+1.25%-0.51%-24.17%+22.63% 14TCr
+1.75%+10.74%-1.31%-16.09% 14TCr
+0.07%-2.34%-58.48%-17.31% 6.57TCr
+1.18%+3.91%+16.07%+0.65% 5.23TCr
-0.52%-0.03%-27.04%-31.75% 4.35TCr
+0.37%+7.04%+14.13%+16.21% 3.84TCr
-0.66%+5.34%+6.24%+45.27% 3.68TCr
+1.26%+6.77%-11.59%-14.67% 2.99TCr
Average -1.05%+4.45%-6.72%+0.62% 8.22TCr
Weighted average by Cap. +1.04%+5.19%-3.40%+0.67%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
-